Treatment(s) already received-Breast reconstruction - Page 2 of 2 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Breast reconstruction Posts on Medivizor

Phase 3 clinical trial evaluating the safety and efficacy of adding docetaxel to doxorubicin and cyclophosphamide chemotherapy in node positive breast cancer patients

Phase 3 clinical trial evaluating the safety and efficacy of adding docetaxel to doxorubicin and cyclophosphamide chemotherapy in node positive breast cancer patients

Posted by on May 30, 2013 in Breast cancer | 0 comments

In a nutshell In this phase 3 clinical trial, two types of adjuvant (a treatment given in addition to a main treatment) chemotherapy regimens were compared in women with node positive breast cancer after surgery to remove the cancer. These were the combination of docetaxel (Taxotere), doxorubicin and cyclophosphamide (TDC) or the combination of...

Read More

Postoperative radiotherapy prevents breast cancer recurrence and prolongs survival

Posted by on Feb 25, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated if strategies to prevent cancer recurrence are associated with prolonged survival 15 years after treatment. Their main findings were that postoperative radiation managed to prevent cancer recurrence and was associated with higher rates of long-term survival. Some background Early breast cancer is often treated...

Read More

Standard Chemotherapy versus Capecitabine (Xeloda) in Older Women with Early-Stage Breast Cancer

Standard Chemotherapy versus Capecitabine (Xeloda) in Older Women with Early-Stage Breast Cancer

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell This trial compared standard chemotherapy regimens and Capecitabine (Xeloda) in women over 65 years old. The main outcome was that standard chemotherapy worked better in this age group. Some background Capecitabine is generally used in breast cancer resistant to other chemotherapy. It is also the first approved treatment that can be...

Read More

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Does Tamoxifen reduce the risk of cancer in a second breast in BRCA1 and BRCA2 carriers?

Posted by on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell The risk of breast cancer is high (~80%) in women who inherit a damaged (mutated) gene called BRCA1 or BRCA 2 (‘BRCA carriers’). Following the first diagnosis, their risk of developing another tumor in the second breast within 10 years is 30%. Some background Some types of breast cancer need estrogen (female sex...

Read More